Drinking Behaviors for Atrial Fibrillation
(FULL-PROOF Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines how alcohol consumption might trigger episodes of atrial fibrillation (AFib), a condition characterized by an irregular heartbeat. Participants will receive daily randomized instructions on whether to avoid alcohol and will wear several monitors to track heart activity and alcohol consumption over two weeks. Eligible participants should have paroxysmal AFib, have experienced a recent episode or be likely to have one soon, and consume alcohol at least once a week. The trial aims to determine if alcohol consumption increases the frequency of AFib episodes. Participants may receive up to $50 for completing the study. As an unphased trial, this study offers a unique opportunity to contribute to understanding the relationship between alcohol consumption and AFib episodes, potentially benefiting future patients.
Do I need to stop my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications. However, it does require that you do not plan to change your AFib management during the two-week monitoring period.
What prior data suggests that this protocol is safe for participants?
Past research has not fully clarified the safety of consuming up to two alcoholic drinks a day for people with atrial fibrillation (AFib). Some studies have shown that even small amounts of alcohol can increase the risk of AFib episodes, with this risk appearing higher in men than in women.
This study will involve only minimal to moderate drinking, defined as no more than two drinks a day for men and one drink a day for women. This controlled approach aims to better understand the short-term effects on AFib episodes while keeping alcohol consumption within a moderate range.
Researchers will closely monitor participants using devices like heart monitors and fitness trackers to ensure safety and collect accurate data.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it offers a fresh approach to understanding atrial fibrillation (AFib) in relation to alcohol consumption. Unlike traditional treatments for AFib, which often focus on medication to control heart rhythm or rate, this study examines how modifying drinking behavior might impact the condition. By using randomized instructions for alcohol consumption, the trial aims to explore whether strategic avoidance or limited intake can reduce AFib episodes. This could lead to personalized lifestyle recommendations that complement existing medical therapies, offering a non-pharmacological way to manage AFib.
What evidence suggests that this trial's treatments could be effective for atrial fibrillation?
Research has shown that drinking alcohol can increase the risk of atrial fibrillation (AFib), a condition where the heart beats irregularly. One study found that each additional drink per day raises the risk of AFib by 6%. Another study demonstrated that alcohol consumption can trigger an AFib episode within a few hours. Even small amounts of alcohol might affect AFib, though the risk is lower. This trial will compare two approaches: one where participants avoid alcohol and another where they do not, to assess the impact on heart rhythm. These findings suggest that alcohol can significantly affect heart rhythm, especially in individuals already diagnosed with paroxysmal AFib, where the condition comes and goes.34678
Who Is on the Research Team?
Gregory Marcus, MD, MAS
Principal Investigator
University of California, San Francisco
Are You a Good Fit for This Trial?
This trial is for individuals with paroxysmal atrial fibrillation, which means they have episodes of irregular heartbeat that come and go. Participants must be willing to follow daily random instructions on alcohol consumption, wear several monitoring devices including an ECG heart monitor, fitness tracker, anklet alcohol monitor, and glucose monitor, as well as complete surveys twice a day.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomly assigned to avoid or not avoid alcohol during a 14-day monitoring period while wearing various monitors and completing surveys
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Randomized instructions
Trial Overview
The study tests the effects of different drinking habits on AFib by randomly assigning participants to either avoid or not avoid alcohol each day. The impact on AFib occurrence is monitored through various wearable devices and daily surveys.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
On a given day of the 14-day study period, participants may be randomly assigned to not avoid consuming alcohol. All participants will be instructed that any alcohol consumed should not be more than 2 drinks in a 24 hour period for men and not more than 1 drink in a 24 hour period for women. The frequency of randomization will be tailored to the baseline usual frequency of alcohol consumption: For example, those who drink an average of 4 days a week/don't drink 3 days a week will have their randomization programmed to assure an average of 7 non-drinking days over the two-week period. Participants will not receive the same randomization assignment more than two consecutive days in a row. Participants will press a button on their continuously recording ECG monitor to time-stamp every alcohol drink consumed.
On a given day of the 14-day study period, participants may be randomly assigned to avoid consuming alcohol. The frequency of randomization will be tailored to the baseline usual frequency of alcohol consumption: For example, those who drink an average of 4 days a week/don't drink 3 days a week will have their randomization programmed to assure an average of 7 non-drinking days over the two-week period. Participants will not receive the same randomization assignment more than two consecutive days in a row.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, San Francisco
Lead Sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Collaborator
Citations
Alcohol consumption and atrial fibrillation risk
The overall meta-analysis showed that a 1 drink/day increase in alcohol consumption increased the risk of AF by 6% (RR: 1.06; 95% CI: 1.03–1.08) (Figure 2).
Alcohol and Atrial Fibrillation: A Sobering Review
Habitual alcohol consumption predisposes to AF by direct effects on left atrial substrate and interaction with other AF risk factors, including hypertension, ...
3.
frontiersin.org
frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.802163/fullAlcohol Consumption and Risk of Atrial Fibrillation: A Dose ...
Our study supported that low alcohol consumption (primarily 0–12 g/day) might be a potentially safe threshold for AF risk. Alcohol showed a ...
Changes in alcohol consumption habits and risk of atrial ...
The incidence rates of sustained heavy drinking, reduced drinking, and absolute abstinence were 4.4, 4.9, and 4.1 per 1000 person-years, respectively.
Alcohol Consumption and Discrete Atrial Fibrillation Events
The present study shows that alcohol consumption substantially increases the chance of a discrete AF episode within a few hours after drinking.
Alcohol Use and Cardiovascular Disease: A Scientific ...
The risk associated with consuming 1 to 2 drinks a day on atrial fibrillation remains unknown. More randomized trials of low to moderate alcohol ...
Alcohol and Atrial Fibrillation - PMC
[35] found that for liquor, the risk of AF was increased when drinking 7–14 and > 14 units of alcohol/week; while in the case of wine, consumption > 14 alcohol ...
Alcohol consumption, cardiac biomarkers, and risk of atrial ...
Alcohol consumption across common types of alcoholic beverages and drinking patterns was associated with an increased AF risk even at low doses.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.